Gi-4000 (Not yet branded)
Other Medications
Description
GI-4000 is a therapeutic cancer vaccine designed to stimulate immune responses against tumor-associated antigens in colorectal cancer patients. This immunotherapeutic agent is formulated to target specific proteins commonly overexpressed in colorectal tumors. Based on clinical trial data, GI-4000 has been evaluated in combination with standard therapies including bevacizumab and chemotherapy regimens like FOLFOX or FOLFIRI for enhanced therapeutic efficacy.
Mechanism of Action
GI-4000 works by presenting tumor-associated antigens to the patient's immune system, specifically targeting proteins that are overexpressed in colorectal cancer cells. The vaccine stimulates both cellular and humoral immune responses, activating T-cells and promoting antibody production against cancer cells expressing these target antigens.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Subcutaneous |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.